As of September 11, 2026, ICICI Bank Ltd. Sponsored (IBN) trades at $29.03. CleaRank Financial AI rates it Buy with a fair value of $36.00, 24.0% above the current price. Wall Street's consensus target is $36.00 across 4 analysts. RSI at 40 is in neutral territory, and the price is below its 50-day average of $29.77.
ICICI Bank Ltd. Sponsored (IBN)
ICICI Bank Ltd. Sponsored NYSE
IBN Price Analysis
Market Metrics
Peer Benchmarking
Valuation vs Sector (Financial Services)
Performance vs KBE
Sector Position Analysis
IBN Analysis
- ICICI Bank's stock is trading below its 50-day moving average, suggesting potential short-term weakness. Consider waiting for a confirmed break above this level before initiating new positions.
- With a median analyst price target of $36.00, there is a notable 24% upside potential from the current price, indicating a favorable risk-reward scenario for long-term investors.
- The stock's trading volume has been significantly below average recently, indicating lower investor interest. Monitor volume trends for signs of increasing conviction.
All 4 Wall Street analysts covering ICICI Bank rate it as Buy or Strong Buy, with a median price target of $36.00, representing a 24% upside from the current price.
Source: Wall Street SummaryAnalysts forecast current year revenue growth of 15.00% to $1367 billion and next year's growth also at 15.00%, indicating strong business expansion prospects.
Source: Wall Street Revenue EstimatesThe most recent quarterly earnings report (July 18, 2026) showed an EPS beat of 2.44% and a positive stock price reaction of 0.97%, signaling improving operational performance.
Source: Earnings DataDespite trading below its 50-day SMA, ICICI Bank remains above its 200-day SMA, providing long-term technical support and indicating that the overall trend may still be intact.
Source: Technical AnalysisKey Statistics
| Market Cap | 208.25B |
|---|---|
| P/E Ratio | 17.70 |
| EPS (TTM) | 1.64 |
| Dividend Yield | 0.00% |
| 52 Week High | 33.03 |
| 52 Week Low | 25.08 |
Earnings & Growth Analysis
Key Risks
Technical Indicators
| RSI (14) | 40.27 |
|---|---|
| MACD | -0.10 |
| SMA 50 | 29.77 |
| SMA 200 | 28.85 |
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
IBN Trade Plans
Specific entry, exit, and risk management levels
🟢 LONG ENTRY (click to switch)
Risk Management
Profit Targets (Based on Conservative Entry)
Growth of $10,000
A $10,000 investment in IBN in September 2016 would be worth about $39,422 today, compared with about $35,030 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in IBN today could grow to about $27,824 by 2036 in the base case, with a bull case near $98,990 and a bear case around $7,821. Projections are statistical simulations, not guarantees.
IBN Stock Price Prediction: 2030
CleaRank's simulation projects a price near $43.71 for IBN by 2030 in the base case, from $29.03 today (1.5x over 4 years). The downside path ends near $19.59. These are outcomes of a Monte Carlo simulation run on IBN's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $21.53 | $32.16 | $48.04 |
| 2028 | $20.19 | $35.62 | $62.84 |
| 2029 | $19.69 | $39.46 | $79.08 |
| 2030 | $19.59 | $43.71 | $97.54 |
| 2031 | $19.74 | $48.42 | $119 |
| 2032 | $20.07 | $53.64 | $143 |
| 2033 | $20.55 | $59.42 | $172 |
| 2034 | $21.15 | $65.82 | $205 |
| 2035 | $21.87 | $72.92 | $243 |
| 2036 | $22.70 | $80.77 | $287 |
Method: 10,000 simulated price paths using IBN's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
